surmount-1 trial tirzepatide weight loss non-diabetic SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, surmount-1 trial tirzepatide weight loss

Get more insights with our podcast Gain unique and valuable insights from Wellmark when you listen to our monthly Health Matters podcast

PlexusDx offers both oral and injectable tirzepatide formulations through licensed 503A compounding pharmacies, allowing patients to choose the delivery method that best suits their needs

Avoiding obesity care violates first, do no harm

Stokes CS, Lammert F

Pharm Med 35 , 1119 (2021)

Among patients who stopped taking tirzepatide, 31.0% doubled their weight loss after two years, 15.2% lost some additional weight, and 9.0% maintained their initial loss, with 55.2% in total maintaining or losing more weight